{
    "nct_id": "NCT06167317",
    "official_title": "A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors",
    "inclusion_criteria": "* Able to understand and give written informed consent.\n* Assigned female or male at birth, 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria by investigator assessment.\n* Organ function requirements:\n\n  * Adequate hematologic function\n  * Adequate hepatic function\n  * Creatinine clearance\n  * Coagulation\n* Tissue requirement:\n\n  * Parts A, B, C, and D:\n\n    * Pre-treatment tumor tissue is required.\n  * Parts A and C backfill biopsy cohorts:\n\n    * Participants must agree to fresh pre- and on-treatment biopsies.\n* Participants assigned male at birth and participants assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception\n* Willing and able to comply with the requirements and restrictions in this protocol\n* Part A (GS-0201 Monotherapy Dose Escalation) Inclusion Criteria:\n\n  * Histologically/cytologically confirmed progressive/advanced solid tumors with selected molecular lesions.\n  * Participants must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy\n* Part B (Dose Expansion) Inclusion Criteria:\n\n  * Disease documented as:\n  * Cohort B1:\n\n    * Histologically or cytologically confirmed progressive/advanced selected solid tumor diagnoses harboring defined molecular lesions\n    * Participants may potentially be required to forgo treatment with approved agent(s) to be able to participate in the study\n  * Cohort B2:\n\n    * Histologically or cytologically confirmed progressive/advanced solid tumor diagnoses harboring defined molecular lesions not included in Cohort B1\n    * Participants must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy\n* Part C (Dose Escalation) Inclusion Criteria:\n\n  * Histologically or cytologically confirmed unresectable locally advanced/metastatic selected solid tumors\n* Part D (Dose Expansion) Inclusion Criteria:\n\n  * Disease documented as:\n  * Cohort D1:\n\n    * Histologically or cytologically confirmed unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)\n  * Cohort D2:\n\n    * Histologically or cytologically confirmed unresectable locally advanced or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ in situ hybridization (ISH-)) breast cancer.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or lactating females\n* Known hypersensitivity to any of the study drugs, its metabolites, or formulation excipients\n* Requirement for ongoing therapy with or use of any prohibited medications described in the protocol\n* Participants with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with findings suggestive of MDS/AML\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of GS-0201\n* The therapies listed below within the specified timeframe:\n\n  * Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, biopsy) < 4 weeks prior to planned Cycle 1 Day 1\n  * Immunotherapy or biologic therapy < 21 days prior to planned Cycle 1 Day 1\n  * Chemotherapy < 14 days prior to planned Cycle 1 Day 1, or < 42 days for mitomycin or nitrosoureas\n  * Targeted small molecule therapy < 14 days prior to planned Cycle 1 Day 1\n  * Receipt of experimental therapy within 21 days or 5 experimental treatment half-lives (whichever is longer) prior to planned Cycle 1 Day 1\n  * Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started < 14 days prior to planned Cycle 1 Day 1 are not permitted. Hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started â‰¥ 14 days prior to planned Cycle 1 Day 1\n  * Radiotherapy within 2 weeks prior to planned Cycle 1 Day 1 and the radiation is not administered to a target lesion\n  * Any prior allogeneic tissue/solid organ transplantation, including allogeneic hematopoietic stem cell transplantation. Participants with a history of autologous hematopoietic stem cell transplantation are also excluded\n* Have not recovered (ie, Grade 1 or lower) from AEs due to a previously administered agent\n* Prior treatment with approved or experimental prohibited agents as detailed in the protocol.\n* Diagnosis of immunodeficiency, either primary or acquired, or requires systemic corticosteroids (> 10 mg of prednisone daily, or equivalent). However, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted\n* Have an active second malignancy\n* Have known active central nervous system (CNS) metastases\n* Participants with carcinomatous meningitis or primary CNS tumors are excluded regardless of clinical stability\n* Meet any of the following criteria for cardiac disease:\n\n  * Myocardial infarction or unstable angina pectoris within 6 months of enrollment\n  * History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication)\n  * QT interval > 470 msec\n  * New York Heart Association Class III or greater congestive heart failure or known left ventricular ejection fraction less than 40%\n* Meet any of the following infectious criteria:\n\n  * Have active serious infection requiring antimicrobials\n  * Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. In participants with a history of HBV or HCV, participants with detectable viral loads will be excluded\n  * Participants who test positive for hepatitis B surface antigen. Participants who test positive for hepatitis B core antibody are eligible with a negative HBV DNA by quantitative Polymerase chain reaction (PCR)\n  * Participants who test positive for HCV antibody. Participants who test positive for HCV antibody are eligible with a negative HCV RNA by quantitative PCR\n  * Participants who test positive for HIV antibody\n* History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or radiation pneumonitis requiring steroids\n* Symptomatic ascites or pleural effusion\n* Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations\n* Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the participant's participation in the study\n* Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of study drug(s) (inactivated, viral vector vaccines, and messenger RNA (mRNA) vaccines are allowed; seasonal vaccines should be up to date prior to planned Cycle 1 Day 1)\n* Parts C (Dose Escalation) and D (Dose Expansion): Combination Cohorts:\n\n  * Participants with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and participants with a history of bowel obstruction or gastrointestinal perforation within 6 months prior to planned Cycle 1 Day 1\n  * Participants who previously received topoisomerase 1 inhibitors or antibody-drug conjugates containing a topoisomerase 1 inhibitor\n  * Known severe intolerance or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous (IV) immunoglobulin preparations; any history of anaphylaxis; history of human anti-human antibody response",
    "miscellaneous_criteria": ""
}